Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Terminated 3Completed 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma 18Lymphoma, Non-Hodgkin 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Hodgkin Disease 11Lymphoma, Large B-Cell, Diffuse 9Central Nervous System Neoplasms 9Leukemia, Myeloid, Acute 8Neuroblastoma 7Multiple Myeloma 7Leukemia 7Brain Neoplasms 7Small Cell Lung Carcinoma 6Sarcoma 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell, Marginal Zone 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Testicular Neoplasms 3Teratoma 3Rhabdoid Tumor 3Medulloblastoma 3Lung Neoplasms 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Testicular Germ Cell Tumor 2Rhabdomyosarcoma 2Recurrence 2

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × etoposide phosphate × Clear all
NCT01411267 2022-04-04

AC220 for Children With Relapsed/Refractory ALL or AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Completed
24 enrolled 14 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00070187 2013-10-17

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Children's Oncology Group

Phase 2/3 Completed
24 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡